Predictive Biosciences Raises $21.75 Million

Predictive Biosciences, a Lexington, Mass.-based developer of intervention diagnostic assays for cancer management, has raised $21.75 million in Series B funding. New Enterprise Associates led the round, and was joined by Kaiser Permanente Ventures and return backers Flybridge Capital Partners and Highland Capital Partners. The company had previously raised a $10 million Series A round.

North AmericaUSBriefs